EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Biomarkers for intestinal damage in pediatric celiac disease

Kamola Sh Usmonova, Svetlana I Geller, Zulhumor E Umarnazarova, Altinoy T Kamilova

Frontiers in Pediatrics · 29.10.2026 · 14

DOI: 10.3389/fped.2026.2000459 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pediatrics, online erschienen am 29.10.2026. Verfasst von Kamola Sh Usmonova und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Republican Specialized Scientific-Practical Medical Center of Pediatrics, Tashkent, Uzbekistan. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Celiac disease (CD) is an immune-mediated enteropathy triggered by gluten in genetically predisposed individuals, affecting around 1% of the global population. Diagnosis relies on serological testing (IgA antibodies to transglutaminase 2 and endomysium), supported by HLA-DQ2/DQ8 typing and duodenal biopsy when indicated. This approach has limitations, including false negatives in IgA deficiency, poor sensitivity in potential or minimal-lesion CD, poor correlation with mucosal healing, and limited ability to predict disease progression. This mini review summarizes non-invasive and minimally invasive biomarkers for the diagnosis and follow-up of CD, with special attention to the pediatric setting. We discuss markers of enterocyte injury (intestinal fatty acid-binding protein, i-FABP; citrulline), immune activation (cytokines, high-mobility group box 1), gluten exposure and barrier function (fecal and urinary gluten immunogenic peptides, zonulin, calprotectin), and molecular signatures emerging from microbiome and multi-omics research. Of these, i-FABP (for diagnosis and follow-up) and gluten immunogenic peptides (for monitoring adherence to a gluten-free diet) appear the most promising. However, assay standardization, age-specific reference ranges, and large-scale prospective pediatric validation remain necessary before routine implementation, and data from regions such as Central Asia are scarce.

Schlagwörter

Stichwörter der Autor:innen

biomarkersceliac diseasechildrencitrullinegluten immunogenic peptidesgluten-free dietintestinal fatty acid-binding proteinzonulin

Autor:innen und Institutionen

  • Department of Gastroenterology, Republican Specialized Scientific-Practical Medical Center of Pediatrics, Tashkent, Uzbekistan.

Zitieren

APA

Sh Usmonova, K., Geller, S. I., Umarnazarova, Z. E., & Kamilova, A. T. (2026). Biomarkers for intestinal damage in pediatric celiac disease. Frontiers in Pediatrics, 14. https://doi.org/10.3389/fped.2026.2000459

Vancouver

Sh Usmonova K, Geller SI, Umarnazarova ZE, Kamilova AT. Biomarkers for intestinal damage in pediatric celiac disease. Frontiers in Pediatrics. 2026;14. doi:10.3389/fped.2026.2000459

BibTeX
@article{ShUsmonova2026,
  author = {Sh Usmonova, Kamola and Geller, Svetlana I and Umarnazarova, Zulhumor E and Kamilova, Altinoy T},
  title = {Biomarkers for intestinal damage in pediatric celiac disease},
  journal = {Frontiers in Pediatrics},
  year = {2026},
  volume = {14},
  doi = {10.3389/fped.2026.2000459}
}
Kostenlos starten →